About: Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
Creator	Zhang, Chao Xu, Yan Liu, Qiang Shi, Fu-Dong Qiu, Wei Zhang, Xinghu Guo, Jun Zhang, C Yang, Huan Bu, Bitao Chen, Jingshan Fan, Moli Huang, Dehui Lau, Alexander Yang, Chun-Sheng Zhang, Mei-Ni Zheng, P Zheng, Pei
source	Medline; PMC
abstract	OBJECTIVE: Disease-modifying drugs (DMDs) may alter the immune status and thus increase the susceptibility to coronavirus disease 2019 (COVID-19) in patients with MS or neuromyelitis optica spectrum disorders (NMOSD). However, evidence supporting this notion is currently lacking. In this study, we conducted a survey on the risk of COVID-19 in patients with MS and NMOSD. METHODS: The survey was conducted through the Chinese Medical Network for Neuroinflammation. Patients in 10 MS centers from 8 cities including Wuhan were included. Information about MS and NMOSD disease duration and the usage of DMDs were collected. Data of suspected cases of COVID-19 were obtained from hospital visits, questionnaires, and patient self-reporting. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed through clinical evaluation by a panel of experts in conjunction with chest CT and viral RNA detection. RESULTS: Eight hundred eighty-two of 1,804 (48.89%) patients with MS and 2,129 of 3,060 (69.58%) patients with NMOSD were receiving DMDs. There were no alterations in the patients' DMD regimen during January 15, 2020, to March 15, 2020, the 3-month period. None of the patients with MS treated with DMDs had COVID-19. However, 2 patients with relapsing NMOSD were diagnosed with COVID-19-related pneumonia. After treatment, both patients recovered from pneumonia and neither patient experienced new attacks due to predisposing SARS-CoV-2 infection in the following 2 months. CONCLUSIONS: No increased risk of COVID-19 infection was observed in patients with MS or NMOSD, irrespective of whether these patients received DMDs. A battery of stringent preventive measures adopted by neurologists to reduce COVID-19 infection in these patients may have contributed to low risk of COVID-19 infection.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1212/nxi.0000000000000787
bibo:pmid	32503092
has license	cc-by-nc-nd
sha1sum (hex)	1c3a805f2af2ea3afee0f51004059871d71a1b08
schema:url	https://doi.org/10.1212/nxi.0000000000000787
resource representing a document's title	Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
has PubMed Central identifier	PMC7286663
has PubMed identifier	32503092
schema:publication	Neurol Neuroimmunol Neuroinflamm
resource representing a document's body	covid:1c3a805f2af2ea3afee0f51004059871d71a1b08#body_text
is schema:about of	named entity 'susceptibility' named entity 'Risk' named entity 'RISK OF' named entity 'DRUGS' named entity 'COVID-19' named entity 'STUDY' named entity 'neuromyelitis optica' named entity 'patients' named entity 'drugs' named entity 'survey' named entity 'NMOSD' named entity 'immune status' named entity 'NMOSD' named entity 'infection' named entity 'COVID-19' named entity 'immune functions' named entity 'NMOSD' named entity 'Beijing' named entity 'China' named entity 'NMOSD' named entity 'infection' named entity 'DMDs' named entity 'COVID-19.' named entity 'fingolimod' named entity 'China' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'DMDs' named entity 'infection' named entity 'fluorescent' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'nasopharyngeal swab' named entity 'Natalizumab' named entity 'DMDs' named entity 'NMOSD' named entity 'DMDs' named entity 'COVID-19 infection' named entity 'Singapore' named entity 'NMOSD' named entity 'NMOSD' named entity 'Neurologists' named entity 'COVID' named entity 'COVID' named entity 'Tongji Hospital' named entity 'Japan' named entity 'COVID' named entity 'short duration' named entity 'Wuhan' named entity 'medical conditions' named entity 'coronavirus disease 2019' named entity 'maintenance therapy' named entity 'China' named entity 'China' named entity 'viral RNA' named entity 'viral RNA' named entity 'Wuhan' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'chest CT' named entity 'Wuhan' named entity 'NMOSD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software